PharmaCyte Biotech, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsPharmaCyte Biotech is a pre-revenue Nevada biotechnology company developing encapsulated live-cell cancer therapies based on the Cell-in-a-Box platform, with its lead candidate CypCaps under an FDA clinical hold since October 2020.
What they do
The company develops cellulose-based live cell encapsulation technology, Cell-in-a-Box, which encapsulates genetically engineered human cells in bioinert cotton-derived capsules for injection near tumors. Its current candidate, CypCaps, is intended to convert a cancer prodrug into a cancer-killing form for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). All know-how for the technology resides with SG Austria Pte. Ltd., and all licensed patents have expired.
Revenue drivers
- Product revenue — No revenue has been reported in any fiscal year from 2022 through 2026 or in any quarter from October 2025 through July 2026; the company has no commercialized product.
- Cell-in-a-Box / CypCaps licensing or collaboration — No licensing, milestone or collaboration revenue appears in the reported financials; the company remains dependent on SG Austria for the underlying technology.
- LAPC development program — The lead program is pre-clinical/clinical-stage and spending on it has been curtailed pending the Scientific Committee and Board review; it generates no revenue today.
Recent performance
Revenue was $0.00 in fiscal 2026 and in each of the four most recent quarters (October 2025 through July 2026). Fiscal 2026 net loss was $19.4M, or diluted EPS of -$2.77, versus fiscal 2025 net income of $30.7M and diluted EPS of $3.19. Operating cash flow was -$5.2M in fiscal 2026, compared with -$3.0M in fiscal 2025. At July 31, 2026, total assets were $36.7M, total liabilities $6.9M, shareholder equity $27.5M and cash and equivalents $17.7M.
Strategy
The Board formed a Strategic Scientific Committee in November 2023, chaired by Dr. Michael Abecassis, and has reduced spending on pre-clinical and clinical activities until its review is complete. The company is reevaluating programs dependent on SG Austria and FDA acceptance of its technologies, including seeking a new framework for the SG Austria relationship. It is also identifying alternative approaches to expand the prodrug/activator technology for cancer treatment into tightly controlled perivascular spaces. The response to the FDA clinical hold on the LAPC IND remains outstanding.
Risks
- FDA clinical hold — The IND submitted September 1, 2020 was placed on clinical hold on October 1, 2020, and the company must provide additional sequencing data, genetic stability studies and a stability study on its final product to have it lifted.
- Dependence on SG Austria and expired patents — All licensed patents have expired and know-how for Cell-in-a-Box solely resides with SG Austria, so the company depends on a third party for the core technology.
- No revenue and recurring losses — Revenue has been $0.00 in each year 2022-2026 and fiscal 2026 produced a $19.4M net loss with $5.2M of operating cash outflow.
- Nasdaq listing risk — The company has disclosed a delisting notice or listing-rule failure event on December 5, 2025, and cites Nasdaq Capital Market listing compliance as a risk.
Outlook
Management states that spending on development programs will remain curtailed until the Scientific Committee completes its evaluation and a new framework for the SG Austria relationship is established. The company continues to work toward addressing the FDA clinical hold on its LAPC IND, but no timeline is given. It is also exploring alternative prodrug/activator approaches in perivascular spaces. No revenue guidance is provided.